Jay Levy, MD

CFAR Leadership Positions

CFAR Mentees


  1. Levy JA, Levy Y. HIV infection: what should be considered in approaches for a cure? AIDS. 2012 Nov 13; 26(17):2253-5. http://www.ncbi.nlm.nih.gov/pubmed/23060292
  2. Levy JA, Autran B, Coutinho RA, Phair JP. 25 Years of AIDS: recording progress and future challenges. AIDS. 2012 Jun 19; 26(10):1187-9. http://www.ncbi.nlm.nih.gov/pubmed/22546989
  3. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. Differential Transmission of HIV Traversing Fetal Oral/Intestinal Epithelia and Adult Oral Epithelia. J Virol. 2012 Mar; 86(5):2556-70. http://www.ncbi.nlm.nih.gov/pubmed/22205732
  4. Killian MS, Levy JA. HIV/AIDS: 30 Years of progress and future challenges. Eur J Immunol. 2011 Dec; 41(12):3401-11. http://www.ncbi.nlm.nih.gov/pubmed/22125008
  5. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, Jha AR, Eccles-James I, Tincati C, Levy JA, Nixon DF, Hecht FM, Barbour JD. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol. 2010 Sep; 30(5):681-92. http://www.ncbi.nlm.nih.gov/pubmed/20571894
  6. Barbour JD, Ndhlovu LC, Xuan Tan Q, Ho T, Epling L, Bredt BM, Levy JA, Hecht FM, Sinclair E. High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One. 2009; 4(2):e4408. http://www.ncbi.nlm.nih.gov/pubmed/19198651
  7. Killian MS, Roop J, Ng S, Hecht FM, Levy JA. CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol. 2009 May; 29(3):311-8. http://www.ncbi.nlm.nih.gov/pubmed/19189205
  8. Sriram U, Wong M, Caillier SJ, Hecht FM, Elkins MK, Levy JA, Oksenberg JR, Baranzini SE. Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy. AIDS Res Hum Retroviruses. 2007 May; 23(5):741-7. http://www.ncbi.nlm.nih.gov/pubmed/17531001
  9. Barbour JD, Sriram U, Caillier SJ, Levy JA, Hecht FM, Oksenberg JR. Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog. 2007 Apr; 3(4):e43. http://www.ncbi.nlm.nih.gov/pubmed/17447840
  10. Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, Levy JA, Busch MP. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses. 2006 Jul; 22(7):640-7. http://www.ncbi.nlm.nih.gov/pubmed/16831088
  11. Killian MS, Fujimura SH, Hecht FM, Levy JA. Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS. 2006 Jun 12; 20(9):1247-52. http://www.ncbi.nlm.nih.gov/pubmed/16816552
  12. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, Bentsen C, Ramstead CA, Nixon DF, Levy JA, Hecht FM. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis. 2006 Mar 1; 42(5):700-8. http://www.ncbi.nlm.nih.gov/pubmed/16447118
  13. Schmidt B, Fujimura SH, Martin JN, Levy JA. Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol. 2006 Jan; 26(1):55-64. http://www.ncbi.nlm.nih.gov/pubmed/16418803
  14. Hasnain M, Sinacore JM, Mensah EK, Levy JA. Influence of religiosity on HIV risk behaviors in active injection drug users. AIDS Care. 2005 Oct; 17(7):892-901. http://www.ncbi.nlm.nih.gov/pubmed/16120505
  15. Lennette ET, Busch MP, Hecht FM, Levy JA. Potential herpesvirus interaction during HIV type 1 primary infection. AIDS Res Hum Retroviruses. 2005 Oct; 21(10):869-75. http://www.ncbi.nlm.nih.gov/pubmed/16225414
  16. Elkins MK, Vittinghoff E, Baranzini SE, Hecht FM, Sriram U, Busch MP, Levy JA, Oksenberg JR. Longitudinal analysis of B cell repertoire and antibody gene rearrangements during early HIV infection. Genes Immun. 2005 Feb; 6(1):66-9. http://www.ncbi.nlm.nih.gov/pubmed/15538390
  17. Martinez-Mariño B, Shiboski S, Hecht FM, Kahn JO, Levy JA. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS. 2004 Oct 21; 18(15):1991-9. http://www.ncbi.nlm.nih.gov/pubmed/15577620
  18. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004 Aug 15; 104(4):942-7. http://www.ncbi.nlm.nih.gov/pubmed/15117761
  19. Martinez-Mariño B, Ashlock BM, Shiboski S, Hecht FM, Levy JA. Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol. 2004 Mar; 24(2):135-44. http://www.ncbi.nlm.nih.gov/pubmed/15024180
  20. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003 Dec 5; 17(18):2581-91. http://www.ncbi.nlm.nih.gov/pubmed/14685052
  21. Mackewicz CE, Craik CS, Levy JA. The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3433-8. http://www.ncbi.nlm.nih.gov/pubmed/12624186
  22. Castelli JC, Deeks SG, Shiboski S, Levy JA. Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals. Blood. 2002 Jun 1; 99(11):4225-7. http://www.ncbi.nlm.nih.gov/pubmed/12010831
  23. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Levy J, Kahn JO. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002 May 24; 16(8):1119-29. http://www.ncbi.nlm.nih.gov/pubmed/12004270
  24. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, Huang L, Levy JA, Liu YJ. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 2001 Aug 15; 98(4):906-12. http://www.ncbi.nlm.nih.gov/pubmed/11493432
  25. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001 Jan 15; 193(2):169-80. http://www.ncbi.nlm.nih.gov/pubmed/11148221
  26. Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A. 2001 Jan 16; 98(2):597-602. http://www.ncbi.nlm.nih.gov/pubmed/11136234
  27. Schito AM, Vittinghoff E, Hecht FM, Elkins MK, Kahn JO, Levy JA, Oksenberg JR. Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy. Blood. 2001 Jan 1; 97(1):214-20. http://www.ncbi.nlm.nih.gov/pubmed/11133763
  28. Kliks S, Contag CH, Corliss H, Learn G, Rodrigo A, Wara D, Mullins JI, Levy JA. Genetic analysis of viral variants selected in transmission of human immunodeficiency viruses to newborns. AIDS Res Hum Retroviruses. 2000 Sep 1; 16(13):1223-33. http://www.ncbi.nlm.nih.gov/pubmed/10957720
  29. Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1685-9. http://www.ncbi.nlm.nih.gov/pubmed/10606091
  30. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J Infect Dis. 1998 Feb; 177(2):470-2. http://www.ncbi.nlm.nih.gov/pubmed/9466540
  31. Sawai ET, Baur AS, Peterlin BM, Levy JA, Cheng-Mayer C. A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J Biol Chem. 1995 Jun 23; 270(25):15307-14. http://www.ncbi.nlm.nih.gov/pubmed/7797518
  32. Kliks SC, Wara DW, Landers DV, Levy JA. Features of HIV-1 that could influence maternal-child transmission. JAMA. 1994 Aug 10; 272(6):467-74. http://www.ncbi.nlm.nih.gov/pubmed/8040983
  33. Sawai ET, Baur A, Struble H, Peterlin BM, Levy JA, Cheng-Mayer C. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1539-43. http://www.ncbi.nlm.nih.gov/pubmed/8108442
  34. Martin NL, Levy JA, Legg H, Weintrub PS, Cowan MJ, Wara DW. Detection of infection with human immunodeficiency virus (HIV) type 1 in infants by an anti-HIV immunoglobulin A assay using recombinant proteins. J Pediatr. 1991 Mar; 118(3):354-8. http://www.ncbi.nlm.nih.gov/pubmed/1705583
  35. Schiødt M, Greenspan D, Levy JA, Nelson JA, Chernoff D, Hollander H, Greenspan JS. Does HIV cause salivary gland disease? AIDS. 1989 Dec; 3(12):819-22. http://www.ncbi.nlm.nih.gov/pubmed/2517203
  36. Edwards JR, Ulrich PP, Weintrub PS, Cowan MJ, Levy JA, Wara DW, Vyas GN. Polymerase chain reaction compared with concurrent viral cultures for rapid identification of human immunodeficiency virus infection among high-risk infants and children. J Pediatr. 1989 Aug; 115(2):200-3. http://www.ncbi.nlm.nih.gov/pubmed/2754549
  37. Greenspan D, Greenspan JS, de Souza Y, Levy JA, Ungar AM. Oral hairy leukoplakia in an HIV-negative renal transplant recipient. J Oral Pathol Med. 1989 Jan; 18(1):32-4. http://www.ncbi.nlm.nih.gov/pubmed/2545870
  38. Cowan MJ, Walker C, Culver K, Weintrub PS, Wara DW, Levy JA. Maternally transmitted HIV infection in children. AIDS. 1988 Dec; 2(6):437-41. http://www.ncbi.nlm.nih.gov/pubmed/3149491
  39. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct; 158(4):862-5. http://www.ncbi.nlm.nih.gov/pubmed/2844921
  40. Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams DI, Kiprov D, Wong R, Kaufman L, Gottlieb MS. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am J Med. 1987 Mar 23; 82(3 Spec No):615-20. http://www.ncbi.nlm.nih.gov/pubmed/3548350
  41. Greenspan D, Greenspan JS, Hearst NG, Pan LZ, Conant MA, Abrams DI, Hollander H, Levy JA. Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis. 1987 Mar; 155(3):475-81. http://www.ncbi.nlm.nih.gov/pubmed/3492574
  42. Kaminsky LS, McHugh T, Stites D, Volberding P, Henle G, Henle W, Levy JA. High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A. 1985 Aug; 82(16):5535-9. http://www.ncbi.nlm.nih.gov/pubmed/2991932